evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

76 questions · 86 findings · 6 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 2.3%GRADE not reported 14 · 16.3%Very low 23 · 26.7%Low 29 · 33.7%Moderate 13 · 15.1%High 5 · 5.8%

Monoclonal antibody vs polyclonal antibody

Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients

Monoclonal antibody showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with polyclonal antibody (low certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Show 7 more findings

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

2 findings from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Participant satisfaction · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review